476 related articles for article (PubMed ID: 33989790)
1. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.
Israelsen SB; Ernst MT; Lundh A; Lundbo LF; Sandholdt H; Hallas J; Benfield T
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1845-1854.e6. PubMed ID: 33989790
[TBL] [Abstract][Full Text] [Related]
2. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
3. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
Lee SW; Ha EK; Yeniova AÖ; Moon SY; Kim SY; Koh HY; Yang JM; Jeong SJ; Moon SJ; Cho JY; Yoo IK; Yon DK
Gut; 2021 Jan; 70(1):76-84. PubMed ID: 32732368
[TBL] [Abstract][Full Text] [Related]
4. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis.
Yan C; Chen Y; Sun C; Ahmed MA; Bhan C; Guo Z; Yang H; Zuo Y; Yan Y; Hu L; Sun Y; Li Y; Zhou Q
Jpn J Infect Dis; 2022 Jan; 75(1):10-15. PubMed ID: 34053958
[TBL] [Abstract][Full Text] [Related]
5. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study.
Lund LC; Kristensen KB; Reilev M; Christensen S; Thomsen RW; Christiansen CF; Støvring H; Johansen NB; Brun NC; Hallas J; Pottegård A
PLoS Med; 2020 Sep; 17(9):e1003308. PubMed ID: 32898149
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis.
Pranata R; Huang I; Lawrensia S; Henrina J; Lim MA; Lukito AA; Kuswardhani RAT; Wibawa IDN
Pharmacol Rep; 2021 Dec; 73(6):1642-1649. PubMed ID: 33840053
[TBL] [Abstract][Full Text] [Related]
7. Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.
Liu JJ; Sloan ME; Owings AH; Figgins E; Gauthier J; Gharaibeh R; Robinson T; Williams H; Sindel CB; Backus F; Ayyalasomayajula K; Parker A; Senitko M; Abraham GE; Claggett B; Horwitz BH; Jobin C; Adelman RM; Diamond G; Glover SC
Am J Gastroenterol; 2021 Aug; 116(8):1638-1645. PubMed ID: 34047305
[TBL] [Abstract][Full Text] [Related]
8. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C
Lucijanic M; Busic N; Stojic J; Barisic-Jaman M; Zagorec N; Lazibat K; Pasaric A; Vrkljan Vuk A; Durlen I; Mitrovic J; Luksic I; Barsic B
Expert Opin Drug Saf; 2023; 22(12):1265-1270. PubMed ID: 37417704
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
11. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.
Ramachandran P; Perisetti A; Gajendran M; Jean-Louis F; Bansal P; Dwivedi AK; Goyal H
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):137-141. PubMed ID: 33252418
[TBL] [Abstract][Full Text] [Related]
12. Estimating COVID-19 Infection and Severity Risks in Patients with Chronic Rhinosinusitis: A Korean Nationwide Cohort Study.
Lee SW; Kim SY; Moon SY; Yang JM; Ha EK; Jee HM; Shin JI; Cho SH; Yon DK; Suh DI
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2262-2271.e2. PubMed ID: 33931377
[TBL] [Abstract][Full Text] [Related]
13. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL
Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359
[TBL] [Abstract][Full Text] [Related]
14. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis.
Patel U; Malik P; Shah D; Patel A; Dhamoon M; Jani V
J Neurol; 2021 Jan; 268(1):240-247. PubMed ID: 32770412
[TBL] [Abstract][Full Text] [Related]
16. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients : A meta-analysis.
Nugroho J; Wardhana A; Maghfirah I; Mulia EPB; Rachmi DA; A'yun MQ; Septianda I
Int J Lab Hematol; 2021 Feb; 43(1):110-115. PubMed ID: 32931146
[TBL] [Abstract][Full Text] [Related]
17. Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19: Evidence from a large population based cohort study.
Meng M; Wu Y; Sha W; Zeng R; Luo D; Jiang R; Wu H; Zhuo Z; Yang Q; Li J; Leung FW; Duan C; Feng Y; Chen H
J Med Virol; 2023 Apr; 95(4):e28720. PubMed ID: 37185863
[TBL] [Abstract][Full Text] [Related]
18. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx).
Martinez-Portilla RJ; Sotiriadis A; Chatzakis C; Torres-Torres J; Espino Y Sosa S; Sandoval-Mandujano K; Castro-Bernabe DA; Medina-Jimenez V; Monarrez-Martin JC; Figueras F; Poon LC
Ultrasound Obstet Gynecol; 2021 Feb; 57(2):224-231. PubMed ID: 33320401
[TBL] [Abstract][Full Text] [Related]
19. Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19.
Wu S; Jin Z; Peng C; Li D; Cheng Y; Zhu R; He J; Wu C
J Glob Health; 2022; 12():05005. PubMed ID: 35198150
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis.
Toubasi AA; AbuAnzeh RB; Khraisat BR; Al-Sayegh TN; AlRyalat SA
Arch Med Res; 2021 Aug; 52(6):656-659. PubMed ID: 33814207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
